Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07595549 · ClinicalTrials.gov registry record · Phase 3
A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity
A Phase 3 study, sponsored by Pfizer.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 954
- Enrollment target
NCT07595549 is a Phase 3 study that is actively recruiting participants, run by Pfizer. The registered enrollment target is 954 participants.
The verdict
NCT07595549, a Phase 3 study, is actively recruiting participants, sponsored by Pfizer.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 954 participants
- Enrollment target
Study Summary
The purpose of this clinical study is to learn about the effects and safety of berobenatide (PF-08653944). This may help people with overweight or obesity lose weight. People in this study may also have type 2 diabetes. About 950 adults will be in this study. Berobenatide will be compared to a placebo. A placebo does not have any medicine in it but looks just like the medicine being studied. Berobenatide or placebo is given by a shot under the skin in the belly area. The objective of the study is to compare the experiences of people receiving berobenatide to those of the people who do not to assess if the study medicine is effective and safe. People will take part in this study for about 20 months. During this time, they will have about 15 study visits at the site. They will also have 2 study visits over the phone.
Interventions
- OTHER Placebo
- DRUG PF-08653944
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 954 participants |
| Start Date | 2026-06-10 |
| Est. Completion | 2028-06-21 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07595549
The ClinicalTrials.gov registry entry for NCT07595549 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 954 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07595549 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07595549 about?
NCT07595549 is a clinical study titled "A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity". The purpose of this clinical study is to learn about the effects and safety of berobenatide (PF-08653944). This may help people with overweight or obesity lose weight. People in this study may also have type 2 diabetes. About 950 adults will be in this study. Berobenatide will be compared to a plac...
What is the current status of trial NCT07595549?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 954 participants. The study started on 2026-06-10. Estimated completion is 2028-06-21.
What interventions are being tested in trial NCT07595549?
The interventions under investigation include: Placebo (OTHER), PF-08653944 (DRUG).
Who is sponsoring clinical trial NCT07595549?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.